Altre lingue SymBio Pharmaceuticals Limited

Azioni

4582

JP3383050006

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 02/05/2024			Variaz. 5gg	Var. 1 gen.
172 ^JPY	-1,15%		-1,71%	-30,36%

13/02	I risultati dell'esercizio FY2023 di SymBio Pharmaceuticals mancano le previsioni a causa di una perdita operativa superiore alle aspettative	MT
08/02	SymBio Pharmaceuticals Limited fornisce una previsione di guadagno per l'anno fiscale 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	19/04
SymBio Pharmaceuticals Limited amended terms of the transaction	18/03
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	13/02
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	08/02
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	08/02
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	15/11
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	14/11
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	14/11
SymBio Pharmaceuticals Limited amended terms of the transaction	10/11
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	06/10/23
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	03/08/23
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	03/08/23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	27/04/23
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	25/04/23
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	24/04/23
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	22/03/23
DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain	16/03/23
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09/02/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue SymBio Pharmaceuticals Limited

Azioni

4582

JP3383050006

Altre lingue

Filtri